1 When Two plus Four Does Not Equal Six: Combining
2 Computational and Functional Evidence Towards Classification
3 of BRCA1 Key Domain Missense Substitutions.
4

5 Author List: Scott T. Pew,[1] Madison B. Wiffler,[2] Alun Thomas,[3] Julie L. Boyle,[4,5] Melissa S.
6 Cline,[6] Nicola J. Camp,[5,7] David E. Goldgar,[5,8] Sean V. Tavtigian[1,5*]
7
Affiliations:

1. Department of Oncological Sciences, University of Utah School of Medicine, Salt Lake City,
Utah, 84112, USA

2. Department of Neurobiology, University of Utah School of Medicine, Salt Lake City, Utah,
84112, USA

3. Division of Epidemiology, Department of Internal Medicine, University of Utah School of
Medicine, Salt Lake City, Utah, 84108, USA

4. Department of Family and Preventive Medicine, University of Utah School of Medicine, Salt
Lake City, Utah, 84108, USA

5. Huntsman Cancer Institute, Salt Lake City, Utah, 84108, USA

6. UC Santa Cruz Genomics Institute, Genomics, University of California, Santa Cruz, CA,
95064, USA

7. Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, Utah,
84108, USA

8. Department of Dermatology, University of Utah School of Medicine, Salt Lake City, Utah,
84108, USA

*   Correspondence: sean.tavtigian@hci.utah.edu.

25
26
27
28

ABSTRACT

Classification of genetic variants remains an obstacle to realizing the full potential of

clinical genetic sequencing. Because of their ability to interrogate large numbers of variants,

multiplexed assays of variant effect (MAVEs) and computational tools are viewed as a critical

part of the solution to variant classification uncertainty. However, the (joint) performance of

these assays and tools on novel variants has not been established. Transformation of the

qualitative classification guidelines developed by the American College of Medical Genetics and

Genomics (ACMG) into a quantitative Bayesian point system enables empirical validation of

strength of evidence assigned to evidence criteria. Here, we derived a maximum likelihood

estimate (MLE) model that converts frequentist odds ratios calculated from case-control data to

proportions pathogenic and applied this model to functional assays, alone and in combination

with, computational tools across several domains of *BRCA1*. Furthermore, we defined

exceptionally conserved ancestral residues (ECARs) and interrogated the performance of

assays and tools at these residues in *BRCA1*. We found that missense substitutions in *BRCA1*

that fall at ECARs are disproportionately likely to be pathogenic with effect sizes similar to that

of protein truncating variants. In contrast, for substitutions falling at non-ECAR positions,

concordant predictions of pathogenicity from functional assay and computational tool fail to

meet the additive assumptions of strength in ACMG guidelines. Thus, collectively, we conclude

that strengths of evidence assigned by expert opinion in the ACMG guidelines are not

universally applicable and require empirical validation.

INTRODUCTION:

ClinVar recently celebrated its 10th anniversary. In that time, as clinical sequencing has become more prevalent, the number of variants cataloged has grown from approximately 27,000 to well over 2 million. Of these 2 million variants, approximately 1.3 million are single nucleotide missense variants (excluding synonymous and nonsense variants), of which roughly 75% remain unclassified (~990,000 variants) [1]. Realizing the full potential of clinical genetic sequencing relies on the ability to accurately and efficiently classify these variants into a realistic continuum from pathogenic to benign. To that end, many multiplexed assays of variant effect (MAVE) and computational tools have been developed. However, the accuracy of these assays and tools, used independently and in combination with one another, towards classifying novel variants identified during sequencing remains to be established.

In 2015, the American College of Medical Genetics and Genomics (ACMG) and the Association for Molecular Pathology (AMP) published guidelines that relied on expert opinion to assign strength of evidence to the various evidence criteria used in sequence variant classification [2]. Subsequently, this approach was found to be compatible with a Bayesian point system where the qualitative assessments of evidence strength categories (supporting, moderate, strong, etc.) were converted to quantitative assertions of odds of pathogenicity (OP) [3, 4]. Shifting to the Bayesian point system makes possible objective evaluation of the strength of evidence the various evidence criteria actually provide. For example, it was recently demonstrated that several computational tools exceeded the qualitative threshold of "supporting" evidence in favor of benignity or pathogenicity and were able to provide "moderate", and in some cases "strong" evidence in favor of benignity or pathogenicity [5].

In the 2015 ACMG/AMP guidelines, well-established functional assays were qualitatively assigned the ability to provide "strong" evidence in favor of pathogenicity or benignity [6]. In the Bayesian point system, this translates to +4 points (18.7:1 odds in favor of pathogenicity) or -4 points (0.053:1 odds in favor of pathogenicity). Yet, limited work has been performed to

quantitatively evaluate the strength of evidence that functional assays provide. As these assays

are not a direct measure of human health, an important step towards applying a specific

functional assay's results to variant classification is validation of the assay's calibration against

human subjects' data from the disease in question.

Furthermore, the 2015 guidelines provided combining rules that prescribed combinations

of different categories of evidence that could move a variant towards classification as

pathogenic or benign. Implicit in the original guidelines, and explicitly stated in the subsequent

work that transformed the guidelines into a Bayesian framework, is the idea that combining

evidence changes the estimate of a sequence variant's probability of pathogenicity. In a

previous publication [7], we noted that a majority of variants in the *BRCA1* RING domain could be

classified by using computational predictions (ACMG codes: PP3/BP4), whether or not a variant

fell at a canonical residue (ACMG code: PM1), functional assay predictions (ACMG codes:

PS3/BS3), and minimal human subjects observational data (ACMG codes: PS4, PM2, BS1).

This led to our conclusion that validation work is needed to ensure that the strength assigned to

these types of evidence was accurate and that addition of Bayesian points associated with

these evidence types was the correct mathematical operation.

As a step towards an empirical test, we derive a maximum likelihood estimate (MLE)

expression for the proportion of variants that are pathogenic within an analytically defined pool.

This model transforms odds ratios (OR) from human subjects' case-control data into a

proportion pathogenic which can then be used to objectively test the strength of evidence a

particular category of evidence provides. Subsequently, we demonstrate two important

applications for such a model using case-control data from *BRCA1* as a test case. First, we use

our model to determine if evidence from several functional assays developed for *BRCA1*

generate the strength of evidence assumed in the 2015 ACMG/AMP guidelines. Second, we

explore the impact of combining functional assay, canonical residue (which we rename

"exceptionally conserved ancestral residues" (ECARs)), and computational tool data to see if

doing so changes the proportion pathogenic of analytical subsets of variants in a way that

matches the additivity expectations set forth in the Bayesian adaptation of the 2015

classification guidelines (Figure 1). Such an approach allows for the quantitative validation of

the qualitative assumptions proposed in variant classification guidelines, a step that is currently

lacking for many evidence criteria used in variant classification.

METHODS:

<u>Maximum Likelihood Estimate of Proportion Pathogenic</u>

In addition to the assumptions in the Bayesian point system ($OP = 81^{\frac{ACMG\ points}{6}}$, prior

probability of pathogenicity = 0.102, points are log odds and therefore additive), this approach

relies on several other assumptions:

1. The OR of a pool of truncating variants in loss of function susceptibility genes

provides a "standard candle" by which one can measure the magnitude of effect of a

given analytically defined pool of variants.

2. An analytically defined pool of variants with an OR similar to that of a pool of

truncating variants consists almost entirely of variants that are pathogenic with an

effect size approximately equal to that of the truncating variants.

3. An analytically defined pool of variants with an OR near 1.0 consists almost entirely

of benign variants.

4. Analytically defined pools of variants with an OR between 1.0 and the OR of

truncating variants can be modeled as a two-component mixture of benign and

pathogenic variants. This assumption is debatable, but importantly, is also testable.

The full derivation of the maximum likelihood estimate model is presented in

supplemental methods. In brief, our model estimates the proportion of observed variants that

are pathogenic, q, from the proportion of all variants that are pathogenic, p, the number of

cases, n, the number of controls, m, the population frequency of disease among individuals who

do not carry a pathogenic variant, δ, and the frequency of disease among individual who are

carriers of a pathogenic variant, δ_1, as shown in Equation 1:

129
$$\hat{q} \;=\; \frac{\hat{p}\left[n\hat{\delta}(1-\delta_1)+\;m(1-\hat{\delta})\delta_1\right]}{\hat{p}\left[n\hat{\delta}(1-\delta_1)+\;m(1-\hat{\delta})\delta_1\right]+(1-\hat{p})\hat{\delta}(1-\hat{\delta})(n+m)} \tag{1}$$

In addition to the variables listed above, our MLE model requires input values for an

odds ratio threshold at which all variants are assumed to be pathogenic. For the odds ratio

threshold in our analysis, truncating variants observed in our case-control data set were

tabulated and a frequentist odds ratio was calculated for this group of variants (21.6, 95% CI:

16.9-27.7). To evaluate the prediction of benign variants we used an alternative OR ceiling

chosen to match the threshold of moderate risk variants (OR = 2.0), which we calculated to be

inflated to 4.4 in our family history enriched case-control dataset [8].

The general population frequency of breast cancer that we used in our analysis was

0.125, as stated in the 2024 update of Cancer Statistics [9].

<u>Identification of Exceptionally Conserved Ancestral Residues in BRCA1 / BARD1</u>

To find evolutionarily distant BRCA1/BARD1 homologs, we started with two alignments,

one of the RING domains of BRCA1 and BARD1 from *Homo sapiens* and *Strongylocentrotus*

purpuratus and a second of the corresponding tandem BRCT (tBRCT) domains. These

alignments were prepared using the structure-guided 3D-Coffee/Expresso mode from the T-

coffee suite of sequence alignment tools [10, 11]. The two resulting alignments were used with

hmmsearch to scan phylogenetically defined subsets of the reference proteome database

maintained at the HMMER website [12]. Hits were defined as gene models with high-scoring

matches to both the RING and tandem BRCT alignments.

At the first round, hits from Placozoa and single celled Holozoans were included, the

alignments rebuilt, and then trimmed back to include clear BRCA1 and BARD1 orthologs from

Trichoplax and *Salpingoeca*. The process was iterated to obtain and include homologs from the

Fungi and then reiterated to obtain and include homologs from three additional eukaryotic

supergroups: Archaeplastida, SAR, and Discoba.

To prepare the final alignments and then define exceptionally conserved ancestral

residues (ECARs), we stratified the hits into a group of BARD1 and relatively BARD1-like hits

and a second group of BRCA1 and relatively BRCA1-like groups; ambiguous hits were placed in

the BRCA1-like group. As before, RING and tBRCT alignments were prepared using 3D-

Coffee/Expresso. Then the BRCA1 and BARD1 alignments were aligned to each other by

introducing gaps across the whole BRCA1 or whole BARD1 alignment, i.e., without modifying

the within-group alignments. The tBRCT alignments were then appended to the RING domain

alignments. Finally, ECARs were defined as (a) positions that were invariant in our existing

metazoan BRCA1 and BARD1 alignments used with Align-GVGD [13, 14], and either (b) also

invariant in the new multi-supergroup alignments or (c) had just one conservative substitution

(i.e., Grantham Variation <65) in the new multi-supergoup alignment.

<u>Functional Assay Results and Computational Predictions</u>

Functional assay scores were obtained from three separate assays that interrogate

missense variants in various domains of BRCA1. These assays were: the 2018 Findlay et al.

saturation genome editing (SGE) assay that interrogated missense and splice junction variants

in the RING and BRCT domain of BRCA1 [15], the 2022 Clark et al. mammalian-2-hybrid (M2H)

assay performed by our laboratory that evaluated missense variants in the RING domain of

BRCA1 [7], and the 2023 Nagy et al. homology-directed repair (HDR) assay that evaluated

missense variants in the coiled-coil domain of BRCA1 [16]. Scores for these assays were

downloaded from MaveDB (SGE and M2H) [17] or from the publication [16]. Thresholds for

functional, indeterminate and non-functional variants were used as defined by the relevant

publication.

Computational tool scores for BayesDel no-AF [18], REVEL [19], and VEST4 [20] were

obtained from the database for Non-synonymous Functional Predictions (dbNSFP) via

Ensembl's web-based Variant Effect Predictor (VEP) [21, 22]. Computational scores for MutPred2

were obtained by downloading a local copy of the software[23]. Scores for AlphaMissense were

downloaded from the original publication [24]. Scores for Align-GVGD (A-GVGD) [25, 26] were

obtained from agvgd.hci.utah.edu using the Human to Sea Urchin alignment. Thresholds for

pathogenic and benign for AlphaMissense, BayesDel, MutPred2, REVEL, and VEST4 were the

supporting pathogenic and supporting benign thresholds from recent calibrations of these tools[5,

27] Align-GVGD, predictions with a score of C0 were interpreted as predicted benign and

predictions with a score of C65 were interpreted as predicted pathogenic with all other scores

being indeterminate.

Estimate of ACMG Points

We interpreted the MLE proportion pathogenic as a posterior probability, PP

(represented as q in the supplemental information and Equation 1), of the variant being

pathogenic and we thus converted this estimate to the appropriate ACMG point via an OP using

a prior probability (P_1) of 0.102 and Equations 2 and 3 below. Both equations and the prior

probability come from Tavtigian et al. [4]. When assigning ACMG points from the estimated

proportion pathogenic, the points that could be awarded were limited to the maximum values

prescribed in the ACMG guidelines [2, 4].

$$PP = (OP \times P_1) \div [(OP - 1) \times P_1 + 1] \qquad (2)$$

$$OP = 81^{\frac{ACMG\ points}{6}} \qquad (3)$$

Case and Control Count Sources and Odds Ratio Calculations

Human subjects' data were obtained from Ambry Genetics and Myriad Genetics. Control

counts are from the non-cancer cohort of gnomAD v2 exomes and gnomAD v3 genomes.

The Ambry dataset initially included data generated by Ambry Genetics from multi-gene

sequencing panels for 165,031 individuals "exempted from review by the Western Institutional

Review Board" [28]. Filters were applied to remove those individuals without breast or ovarian

cancer, individuals who lacked BRCA1 sequence data, individuals of Ashkenazi Jewish

ancestry, and individuals with pathogenic or likely pathogenic variants in *TP53*, *BRCA2*, and

PALB2. This resulted in a final dataset of 91,367 individuals, of which 2,930 had variants in

BRCA1. Of these 2,930 individuals, 498 had missense variants that fell within the RING (amino

acids 1-100), coiled-coil (amino acids 1,280-1,576), or BRCT domain (amino acids 1,650-

1,863).

The Myriad dataset initially included data generated by full-sequence BRCA1/2 tests

performed by Myriad Genetics from 60,607 individuals. For these, a test request form must have

been completed by the ordering health care provider, and the form must have been signed by

an appropriate individual indicating that "informed consent has been signed and is on file" [13, 28,

29]. Filters were applied to remove those individuals without breast or ovarian cancer, individuals

who lacked *BRCA1* sequence data, individuals of Ashkenazi Jewish ancestry, and individuals

with pathogenic or likely pathogenic variants in *BRCA2*. This resulted in a final dataset of 35,088

individuals, of which 4,005 had variants in *BRCA1*. Of these 4,005 individuals, 524 had

missense variants that fell within the RING, coiled-coil, or BRCT domain.

The gnomAD dataset is a composite of v2 non-cancer exomes and v3 non-cancer

genomes that initially included 192,502 individuals. Filters were applied to remove individuals of

Finnish or Ashkenazi Jewish ancestry and to remove common missense variants (allele

frequency > 0.000271). This resulted in a final dataset of 169,933 individuals, of which 955 had

missense variants that fell within the *BRCA1* RING, coiled-coil, or BRCT domain.

Combining these datasets resulted in a final dataset of 126,455 breast and ovarian

cases from Ambry and Myriad and 169,933 controls from gnomAD v2 and v3. Ethnicity for this

dataset was split into four groups: non-Finnish European, Ashkenazi Jewish, Finnish, and all

others. As stated previously, Ashkenazi Jewish and Finnish individuals were removed due to

strong founder effects in these populations.

After filtering, the data for *BRCA1* were formatted into a table that indicated the ethnicity

of the individual, whether an individual was a case or control, how the variant was classified by

each functional assay and computational tool, and whether the variant fell at an ECAR. Logistic

regression was performed using Stata 17.0 (Statacorp) to calculate frequentist odds ratios.

Proportions pathogenic were calculated using a custom R script. Following logistic regression,

the Wald test was performed to determine statistical significance between strata in each

analysis.

RESULTS:

Exceptionally Conserved Ancestral Residues in *BRCA1 / BARD1*

BRCA1, *BARD1*, and homologs that have been studied in the Archaeplastida are

thought to have evolved from a common ancestor gene with a 5' RING domain and 3' tandem

BRCT (tBRCT) domain that was present in an ancient eukaryote before the divergence of

Amorphea and Archaeplastida [30]. Protein multiple sequence alignment (PMSA) based

hmmsearch [12] identified clear *BRCA1* and *BARD1* orthologs in *Trichoplax* and more distantly

related single-celled members of Holozoa, plus homologs (some of which may be true

orthologs) in the Holomycota, Archaeplastida, SAR, and Discoba. Although the root of the

eukaryotic phylogeny remains unclear [31, 32], the resulting PMSA should be sufficient to identify

positions in human *BRCA1* and *BARD1* where the amino acid present in the human sequence

has been inherited identical by descent from a common ancestor of the Amorphea and is under

constraint in 2-3 additional eukaryotic supergroups. We identified 14 such residues: the 8

residues that define the C3HC4 RING motif plus 6 additional residues in the tBRCT domain

(Table 1, Figure S1), and hereafter refer to them as Exceptionally Conserved Ancestral

Residues (ECARs).

Of the 82 possible snMSs at ECARs, 78 resulted in a non-functional assay result via the

SGE assay. The four exceptions were C24F, C61R, T1700S (which was not interrogated in the

SGE assay), and W1718S. C24F, C61R, and W1718S had indeterminate results in the SGE

assay, however, C24F and C61R were scored as loss of function in the M2H assay.

Using the pathogenic strong thresholds established in Pejaver et al, we also tabulated

the number of substitutions at ECARs that were extreme enough to receive +4 ACMG points

from computational tools (Table 1). MutPred2 predicted 0 of the possible ECAR substitutions to

be extreme enough to receive +4 ACMG points. BayesDel predicted 56 of the 82 possible

substitutions to be extreme enough for +4 ACMG points, and these constituted 56 of the 73

such RING and tBRCT +4 results called by BayesDel. AlphaMissense, REVEL, and VEST4 had

totals that fell between MutPred2 and BayesDel.

A separate analysis was performed using the BayesDel threshold prescribed in the

ENIGMA BRCA1 Variant Curation Expert Panel (VCEP) guidelines ($\geq$ 0.28) as well as for Align-

GVGD using C65 as a pathogenic prediction threshold[33]. Under these parameters, many more

of the ECARs identified in the tBRCT domains were predicted to be pathogenic (Table 1). A

summary of computational tool performance at ECAR positions and individual scores for each

substitution are available in Supplementary Table 1.

Functional Assay Performance

In our initial analysis, we used an OR threshold set to that of the OR of nonsense

substitutions observed in our case control dataset, which was 21.6 (95% CI: 16.9-27.7). The

results of our analysis of functional assay performance using this OR threshold are presented in

Table 2. As stated in the Methods section, ACMG points awarded are limited to the maximum

number of points outlined in the ACMG guidelines and subsequent transformation to a Bayesian

framework.

In the M2H assay, which interrogates variants in the RING domain of BRCA1, variants

that were functional and were observed in our case control dataset yielded an adjusted OR

close to 1 (1.21, 95% CI: 0.85-1.72) indicating a group of variants composed almost entirely of

benign variants. The proportion pathogenic for this group was estimated to be 0.01 which

translates to -3 points in the ACMG points system. There were insufficient observations for

variants that were categorized as indeterminate to compute an OR or a proportion pathogenic.

The group of all variants that were non-functional and observed in our dataset had an adjusted

OR of 22.6 (95% CI: 12.9-39.5) which is similar to that of nonsense substitutions in our dataset,

indicating a group consisting of mostly pathogenic variants. This analytical subset had a

proportion pathogenic of 1.00, which would be assigned the full +4 points that are available for

non-functional assay results in the ACMG guidelines.

In addition to evaluating the strength of evidence of a single evidence category, our

model can also test the strength of combined evidence categories. To this end, we stratified the

non-functional variants from the M2H assay into two groups: variants that fell at the ECARs we

identified from the PMSA, and all other residues (ACMG code: PM1). For variants that were

non-functional and fell at an ECAR, the computed OR was 24.8 (95% CI: 13.5-45.6), slightly

higher than the group of all non-functional variants and indicating a subset of variants with

similar risk to that of truncating variants. The computed proportion pathogenic remained at

1.00. Combining the +4 points from functional assay and +2 points available from ECARs

(PM1), results in +6 points for this group of variants. Thus, using these two evidence criteria

alone, these variants reach the likely pathogenic threshold.

The computed OR for non-functional variants that fell at other residues was 9.89 (95%

CI: 2.23-43.9), indicating that this group of variants confers less risk than those that are non-

functional and fall at an ECAR. The proportion pathogenic for the non-functional variants that

fell at other residues was 0.74, sufficient for +4 points from functional assay. In the absence of

other evidence, this group would remain VUS**.**

The SGE assay, which evaluated variants across the RING and tBRCT domains of

BRCA1, had similar results to the M2H assay. However, the group of variants that were

functional via SGE yielded an OR close to 1 (0.80, 95% CI: 0.64-1.00) and a proportion

pathogenic of 0.00, which would qualify for the full -4 points available from a functional assay

result. For variants that were non-functional, the SGE assay had an OR of 16.3 (95% CI: 11.6-

27.7) and a proportion pathogenic of 0.88 which would confer the full +4 points for these

variants. Stratification of non-functional variants at ECARs versus non-functional variants at

other residues again demonstrates that non-functional variants at ECARs have enough strength

of evidence to reach the likely pathogenic threshold. The ORs for these groups were 26.2 (95%

CI: 14.3-48.1) and 12.0 (95% CI: 7.91-18.1), respectively, with a χ^2 p-value of 0.037. Non-

functional variants at ECARs had a proportion pathogenic of 1.00 which equates to +6 points.

Variants that are non-functional and fall at other residues have a proportion pathogenic of 0.71,

just above the threshold required for +4 points; moreover, the χ^2 result provides evidence that

the two groups are indeed distinct.

Whereas the M2H and SGE assays largely confirmed the assumptions of strength of

evidence in the ACMG guidelines, the results from the HDR assay in the coiled-coil domain of

BRCA1 show a different result. The ORs for the functional and non-functional groups were 1.32

(95% CI: 0.76-2.29) and 1.48 (95% CI: 0.87-25.2) respectively, indicating that both groups of

variants are largely benign. The group of functional variants had a calculated proportion

pathogenic of 0.05 which would only justify -1 point. The group of non-functional variants had a

proportion pathogenic of 0.06 which is insufficient to justify evidence in either direction (towards

pathogenicity or benignity) and thus 0 points. It is noted that there were few observations in our

case-control dataset that both fell within this domain and were included in the functional assay.

Additionally, many of the variants interrogated by this assay do not appear to be attainable via a

single nucleotide substitution to the canonical BRCA1 transcript, which is the type of substitution

that is the primary focus of this analysis.

Due to these limitations, we performed a separate analysis focusing on structurally

informed predictions of damage to coiled-coil interactions at the alpha helix spanning amino

acids 1,400-1,418, i.e., non-conservative substitutions at the helix *a* and *d* positions plus any

substitutions to proline falling in the same interval. With only one observation in a case

(p.L1407R) against four control observations (one each for p.M1400K, p.L1404R, p.L1407H,

and p.L1414P), the observational evidence weighs against the hypothesis that missense

substitutions in this domain are pathogenic (Table 2, final line).

Combining SGE Functional Results and Computational Predictions

To explore the impact of combining functional assay results and computational tool

predictions we stratified variants from the SGE assay by computational prediction (pathogenic,

indeterminate, and benign) from six computational tools (Align-GVGD, AlphaMissense,

BayesDel, MutPred2, REVEL, and VEST4) using thresholds outlined in Pejaver *et al*. or those

stated in the Methods section [5]. This analysis was performed only on results from the SGE

assay which interrogated both the RING and BRCT domains of *BRCA1* and thus had sufficient

observations for stratification.

Combining Non-functional Assay Results with Computational Predictions for Substitutions

Falling at Non-ECAR Positions

The OR for the group of variants that were categorized as non-functional via the SGE

assay and did not fall at ECARs was 12.0 (95% CI: 7.91-18.1) with a proportion pathogenic of

0.71, just reaching +4 ACMG points, as stated previously. By stratifying these variants by

computational prediction, we can evaluate the effect of combining functional assay and

computational prediction data toward variant classification (Table 3). It should be noted that if

the computational predictions unanimously agreed with the functional assay result, the OR,

estimated proportion pathogenic, and ACMG points would remain unchanged after adding in

evidence from computational tools. Thus, the true utility of computational predictions in this

analysis stems from the ability of the computational tool to accurately disagree with – and

thereby stratify – the functional assay result.

Of the computational tools included in our analysis, pathogenic predictions from

BayesDel and REVEL did not increase the OR or the estimated proportion pathogenic when

combined with the non-functional assay data. It is noted that the breakdown of predictions for

BayesDel and REVEL are the same. This is not unexpected as both are meta-callers,

incorporating predictions from individual callers into a weighted overall score, and share several

of the same individual components [18, 19].

On the other hand, pathogenic predictions from Align-GVGD, AlphaMissense, MutPred2,

and VEST4 did increase the OR and thus the estimated proportion pathogenic from that of the

functional assay result, albeit not sufficiently to meet the expected value of +5 ACMG points.

Additionally, Align-GVGD, AlphaMissense, MutPred2, and VEST4 decreased the ORs

and estimated points for variants that were non-functional via assay and either indeterminate or

benign by computational prediction. Notably, Align-GVGD and MutPred2 yielded results in the

expected descending proportion pathogenic order from non-functional computationally

pathogenic to non-functional computationally benign. For Align-GVGD, the 23 unique variants

(106 case-control observations) that were non-functional via assay and predicted pathogenic

had an OR of 14.9 (95% CI: 7.97-28.0) and a proportion pathogenic of 0.79, which equates to

+4 ACMG points. The 20 unique variants (82 case-control observations) that were non-

functional via assay and computationally indeterminate had an OR of 10.9 (95% CI: 5.72-20.6)

and a proportion pathogenic of 0.68, which equates to +3 ACMG points. Finally, the 15 unique

variants (20 case-control observations) that were non-functional and predicted benign had an

OR of 6.80 (95% CI: 2.24-20.6) and a proportion pathogenic of 0.49, which equates to +2

ACMG points. Corresponding results for the other computational tools are summarized in Table

3.

<u>Combining Functionally Normal Assay Results with Computational Predictions for Substitutions</u>

<u>Falling at Non-ECAR Positions</u>

For the analysis of variants that were functionally normal via SGE and did not fall at

ECARs, we used an alternative OR ceiling at the threshold for moderate risk variants (OR = 2 in

a general population, which is inflated to approximately 4.4 in our dataset) to evaluate evidence

against pathogenicity. For the SGE assay, functional variants had an OR of 0.8 (95% CI: 0.64-

1.00) and an estimated proportion pathogenic of 0.00, sufficient for the -4 ACMG points

allowable from functional assays. The results of stratification by computational tool are

presented in Table 4.

Compared to other computational tools, BayesDel and REVEL made few predictions of

benignity even though this group of variants were functional via the assay. Interestingly, REVEL

did not predict any of the variants in this dataset to be benign and BayesDel only predicted five

unique variants to be so. For REVEL, the ORs for variants predicted to be pathogenic or

indeterminate remained close to 1.0, 1.08 (95% CI: 0.77-1.52) and 0.49 (95% CI: 0.36-0.68),

respectively.

Excepting MutPred2 and REVEL, pathogenic predictions from the other computational

tools elevated the OR, proportion pathogenic, and ACMG points for the subset of functional

variants from the assay (see Table 4). Discordance between functional assay and

computational tool is of sufficient magnitude to move variants in these analytical subsets from

likely benign (-1 to -6 ACMG points) up to VUS (0-5 ACMG points). Furthermore, predictions of

pathogenicity from Align-GVGD, AlphaMissense, BayesDel-VCEP, and VEST4 on functionally

normal variants created subsets that were statistically significantly distinct from benign

predictions on functionally normal variants.

Of particular note is the series of ORs, proportions pathogenic, and ACMG points that

result from stratification by Align-GVGD, AlphaMissense, and BayesDel. These tools were the

only ones of those evaluated in this study that yielded three appropriately ordered analytical

subsets for functional variants from the SGE assay. The ORs for pathogenic, indeterminate,

and benign Align-GVGD predictions were 2.53 (95% CI:1.00-6.38), 1.45 (95% CI: 0.93-2.26),

and 0.58 (95% CI: 0.44-0.77) respectively. The corresponding proportions pathogenic were

0.32, 0.10, and 0.00, corresponding to ACMG points of 1, 0, and -5 respectively.

DISCUSSION:

In the above analysis, we provide an MLE model that links the OR from a case-control

analysis to an estimate of the proportion of variants that are pathogenic and thereby to the odds

of pathogenicity and corresponding ACMG points. We also defined and identified ECARs within

the RING and tBRCT domains of *BRCA1*. We then demonstrated important use cases of our

MLE model in evaluating the strength of evidence for several functional assays alone and in

combination with ECAR data and computational tool predictions, as summarized in Figure 2.

This work takes an important step in the ability to empirically test whether the assertions of the

strength of evidence for different evidence types, and the combinations thereof, proposed in the

2015 ACMG/AMP guidelines are valid. And it does so in a way that takes account of effect size

while avoiding the circularities inherent in analyses that are based on re-call.

We analyzed the performance of several computational tools at the ECARs that were

identified through our multi-supergroup PMSA. While some tools, especially AlphaMissense,

BayesDel, and REVEL, seemed to be "aware" of the ECARs in the RING domain, far fewer

substitutions at ECARs in the tBRCT domain had high enough scores to receive +4 ACMG

points. Additionally, there was variability between tools in the number of ECARs that received

extreme enough scores to award +4 ACMG points (0 substitutions at ECARs received +4 from

MutPred2, while 56 did from BayesDel), even though most computational tools incorporate

evolutionary conservation into their predictions. This discrepancy may arise due to limitations in

creating deep, multi-supergroup PMSAs using currently available automated alignments. By

manually curating our alignment, we were able to include sequences that contained inserts of

various sizes between the RING and tBRCT domains that would likely be discarded by

automated approaches.

From our analysis of the strength of evidence that functional assays provide, we

conclude that functional assays can indeed reach a quantitative threshold that aligns with the

recommendations outlined in the ACMG guidelines, in both the benign and pathogenic

directions. However, the strength of evidence can differ in the pathogenic and benign directions

and not all assays validate as a predictor of pathogenicity. For example, variants with functional

results from the M2H assay in the RING domain of BRCA1 fell just short of the OP threshold for

-4 points, while non-functional results provided sufficient evidence for +4 points. Furthermore,

our structurally informed analysis of predicted loss of function substitutions in the core alpha

helix of the *BRCA1* coiled coil domain (amino acids 1,400 – 1,418) weigh against the hypothesis

that missense substitutions in this domain can be pathogenic. Thus, this study provides further

evidence that careful evaluation of functional assays is required prior to their use in clinical

settings and that +/- 4 points should not be assigned carte blanche [6].

For substitutions that fell at ECAR positions, we found that predictions of pathogenicity

from functional assay are additive in a manner consistent with ACMG guidelines (i.e +4 points

from PS3 and +2 points from PM1 = +6). Furthermore, these variants had an effect size similar

to that of truncating variants. However, for non-functional substitutions that fell at non-ECAR

positions, we found that concordant predictions of pathogenicity from functional assay and

computational tool are not additive as proposed in the ACMG guidelines (i.e +4 points from PS3

and +1 point from PP3 = +5). Specifically, we found that none of the tools included in this

analysis were able to raise the proportion pathogenic as expected and these pools of variants

only provided enough strength of evidence for +4 points. However, for functionally normal

variants in the assay, concordant predictions in the benign direction from several computational

tools did meet the ACMG combining expectations (i.e -4 points from BS3 and -1 point from BP4

= -5).

Conflicting predictions between functional assay and computational tools were able to

modulate effect size, estimated proportions pathogenic and ACMG points for the resulting

analytical subsets. For substitutions that were non-functional via the SGE assay and fell at non-

ECAR positions, benign or indeterminate predictions from several computational tools were

found to deprecate the evidence from the functional assay. For example, after stratification by

Align-GVGD, less than half (23/58) of the observed variants retained a sufficient proportion

pathogenic for +4 ACMG points. For substitutions that were functional via the SGE assay,

pathogenic or indeterminate predictions from several computational tools created statistically

different effect sizes after stratification.

While the ACMG expectations were not met for all instances of functional assay and

computational tool combinations, we note that two tools, Align-GVGD and MutPred2, were able

to produce appropriately ordered series of ORs, proportions pathogenic, and ACMG points for

predicted pathogenic variants. On the benign side, only Align-GVGD and AlphaMissense yielded

the appropriately ordered series of ORs, proportions pathogenic, and ACMG points. Thus Align-

GVGD was the only computational tool that was able to appropriately stratify non-functional and

functional results in both the pathogenic and benign directions. While Align-GVGD was not

explicitly trained on *BRCA1*, it was optimized for this gene. Therefore, future studies will need

to interrogate the performance of this and other tools on a diverse set of genes.

This study focused on functional assay results individually and in combination with

ECARs and computational tool predictions, however, this method can be applied to any

classifier or combination of classifiers. We chose *BRCA1* as a test case, in part, because of the

robust case-control dataset that is available for this gene. In instances where case-control data

may be more limited, a similar analysis could be conducted by pooling a defined set of genes

and evaluating the ability of the classifier in question to generate ordered series of ORs with

appropriate effect sizes. Effective evaluation of variant effect predictors will increasingly rely on

availability of case data to match the publicly available control data that can obtained from

sources such as gnomAD, the UK Biobank, and the All of Us Projects.

Additionally, this analysis provides a way of evaluating the strength of evidence that a

particular classifier, or combinations of classifiers, provides in relation to an analytical subset of

variants (i.e predicted benign, predicted pathogenic). It does not evaluate the pathogenicity of

an individual variant. Thus, even though an assay's predictions or combinations of an assay

and computational tool perform well in this analysis, analytical subsets of variants may contain

individual variants that differ in their unique role in disease from the group at large.

Beyond the findings from this study, further considerations may need to be adapted over

time and depending on use case. For example, our analysis looks at two possible OR

thresholds that one could use, that of nonsense variants in our dataset (OR = 21.62) and the

ENIGMA-defined threshold for moderate risk variants in our dataset (OR = 4.4). While the

resolution of which threshold to use is beyond the scope of this work; we note that careful

selection of a standard candle by which to interpret subsets of variants will be critical.

These findings are important to bear in mind as assays and other tools are validated for

use in variant classification. Often, functional assays and computational tools are validated by

re-call, using the raw classifications of variants to assess the performance of the new assay or

tool. It is known that this strategy leads to overly confident evaluations of variant effect

classifiers due to circularities inherent in training and validation datasets [34]. Furthermore, it may

be the case that variants that are already securely classified are different from variants that

remain to be classified and may have other characteristics, such as disproportionately falling at

ECARs, that potentially inflate the strength of evidence the new assay or tool naively seems to

provide. Therefore, it is important to conduct analyses that assess effect size as a validation

step – and be prepared to modify or reject calibrations that do not reach the required effect size.

This study provides a means to do this without the need for re-call, provided there are sufficient

case-control or family history data available.

In 2018, we proposed a bidirectional feedback model wherein empirical measurements

of strength of evidence steadily improve the rigor of variant classification [4] thereby providing

stepping stones towards clinical validity. This work provides a practical model that can be used

to achieve that end. Our MLE model assumes an underlying two-component mixture model in

which stratification would yield subsets of variants with effect size similar to that of truncating

variants (for loss of function susceptibility genes) and a subset with an effect size similar to

benign variants. However, this Platonic Form of clear-cut analytical subsets may not be what is

observed in practice. Indeed, in our analysis, variants that had non-functional assay results and

did not fall at ECARs had ORs above the benign threshold but below the OR for truncating

variants. Future work, therefore, should focus on strategies to further resolve variant

stratification on the continuum from benign to pathogenic.

The combination of functional assays and computational tools have been heralded as the path

forward to resolve variant classification uncertainty due to their ability to predict the outcomes of

large sets of variants [7, 35, 36]. However, as shown in this study, current assays, tools, and their

combinations may not meet the quantitative strength assigned in classification guidelines or

published calibration studies. Additional refinement, careful calibration, and rigorous validation

of variant classifiers is critical to ensure that those who use these tools are aware of the strength

of evidence they provide.

ACKNOWLEDGEMENTS:

We would like to thank Marcy Richardson, Tina Pesaran, Colin Young, and Steven Harrison

from Ambry Genetics for thoughtful discussion and database support. We would also like to

thank AC Tan, Jay Gertz, and Pinar Bayrak-Toydemir for thoughtful reading and comments on

the manuscript.

REFERENCES:

(1) Landrum, M. J.; Lee, J. M.; Riley, G. R.; Jang, W.; Rubinstein, W. S.; Church, D. M.; Maglott,

D. R. ClinVar: public archive of relationships among sequence variation and human phenotype.

Nucleic Acids Res **2014**, *42* (Database issue), D980-985. DOI: 10.1093/nar/gkt1113 From NLM

Medline.

(2) Richards, S.; Aziz, N.; Bale, S.; Bick, D.; Das, S.; Gastier-Foster, J.; Grody, W. W.; Hegde,

M.; Lyon, E.; Spector, E.; et al. Standards and guidelines for the interpretation of sequence

variants: a joint consensus recommendation of the American College of Medical Genetics and

Genomics and the Association for Molecular Pathology. *Genet Med* **2015**, *17* (5), 405-424. DOI:

10.1038/gim.2015.30 From NLM Medline.

(3) Tavtigian, S. V.; Greenblatt, M. S.; Harrison, S. M.; Nussbaum, R. L.; Prabhu, S. A.; Boucher,

K. M.; Biesecker, L. G.; ClinGen Sequence Variant Interpretation Working, G. Modeling the

ACMG/AMP variant classification guidelines as a Bayesian classification framework. *Genet Med*

2018, *20* (9), 1054-1060. DOI: 10.1038/gim.2017.210 From NLM Medline.

(4) Tavtigian, S. V.; Harrison, S. M.; Boucher, K. M.; Biesecker, L. G. Fitting a naturally scaled

point system to the ACMG/AMP variant classification guidelines. *Hum Mutat* **2020**, *41* (10),

1734-1737. DOI: 10.1002/humu.24088 From NLM Medline.

(5) Pejaver, V.; Byrne, A. B.; Feng, B. J.; Pagel, K. A.; Mooney, S. D.; Karchin, R.; O'Donnell-

Luria, A.; Harrison, S. M.; Tavtigian, S. V.; Greenblatt, M. S.; et al. Calibration of computational

tools for missense variant pathogenicity classification and ClinGen recommendations for

PP3/BP4 criteria. *Am J Hum Genet* **2022**, *109* (12), 2163-2177. DOI:

10.1016/j.ajhg.2022.10.013 From NLM Medline.

(6) Brnich, S. E.; Abou Tayoun, A. N.; Couch, F. J.; Cutting, G. R.; Greenblatt, M. S.; Heinen, C.

D.; Kanavy, D. M.; Luo, X.; McNulty, S. M.; Starita, L. M.; et al. Recommendations for application

of the functional evidence PS3/BS3 criterion using the ACMG/AMP sequence variant

interpretation framework. *Genome Med* **2019**, *12* (1), 3. DOI: 10.1186/s13073-019-0690-2 From

NLM Medline.

(7) Clark, K. A.; Paquette, A.; Tao, K.; Bell, R.; Boyle, J. L.; Rosenthal, J.; Snow, A. K.; Stark, A.

W.; Thompson, B. A.; Unger, J.; et al. Comprehensive evaluation and efficient classification of

BRCA1 RING domain missense substitutions. *Am J Hum Genet* **2022**, *109* (6), 1153-1174. DOI:

10.1016/j.ajhg.2022.05.004 From NLM Medline.

(8) Spurdle, A. B.; Greville-Heygate, S.; Antoniou, A. C.; Brown, M.; Burke, L.; de la Hoya, M.;

Domchek, S.; Dork, T.; Firth, H. V.; Monteiro, A. N.; et al. Towards controlled terminology for

reporting germline cancer susceptibility variants: an ENIGMA report. *J Med Genet* **2019**, *56* (6),

347-357. DOI: 10.1136/jmedgenet-2018-105872 From NLM Medline.

(9) Siegel, R. L.; Giaquinto, A. N.; Jemal, A. Cancer statistics, 2024. *CA Cancer J Clin* **2024**, *74*

(1), 12-49. DOI: 10.3322/caac.21820 From NLM Medline.

(10) Wallace, I. M.; O'Sullivan, O.; Higgins, D. G.; Notredame, C. M-Coffee: combining multiple

sequence alignment methods with T-Coffee. *Nucleic Acids Res* **2006**, *34* (6), 1692-1699. DOI:

10.1093/nar/gkl091 From NLM Medline.

(11) Armougom, F.; Moretti, S.; Poirot, O.; Audic, S.; Dumas, P.; Schaeli, B.; Keduas, V.;

Notredame, C. Expresso: automatic incorporation of structural information in multiple sequence

alignments using 3D-Coffee. *Nucleic Acids Res* **2006**, *34* (Web Server issue), W604-608. DOI:

10.1093/nar/gkl092 From NLM Medline.

(12) Potter, S. C.; Luciani, A.; Eddy, S. R.; Park, Y.; Lopez, R.; Finn, R. D. HMMER web server:

2018 update. *Nucleic Acids Res* **2018**, *46* (W1), W200-W204. DOI: 10.1093/nar/gky448 From

NLM Medline.

(13) Tavtigian, S. V.; Byrnes, G. B.; Goldgar, D. E.; Thomas, A. Classification of rare missense

substitutions, using risk surfaces, with genetic- and molecular-epidemiology applications. *Hum*

Mutat **2008**, *29* (11), 1342-1354. DOI: 10.1002/humu.20896 From NLM Medline.

(14) Young, E. L.; Feng, B. J.; Stark, A. W.; Damiola, F.; Durand, G.; Forey, N.; Francy, T. C.;

Gammon, A.; Kohlmann, W. K.; Kaphingst, K. A.; et al. Multigene testing of moderate-risk

genes: be mindful of the missense. *J Med Genet* **2016**, *53* (6), 366-376. DOI:

10.1136/jmedgenet-2015-103398 From NLM Medline.

(15) Findlay, G. M.; Daza, R. M.; Martin, B.; Zhang, M. D.; Leith, A. P.; Gasperini, M.; Janizek, J.

D.; Huang, X.; Starita, L. M.; Shendure, J. Accurate classification of BRCA1 variants with

saturation genome editing. *Nature* **2018**, *562* (7726), 217-222. DOI: 10.1038/s41586-018-0461-

z From NLM Medline.

(16) Nagy, G.; Diabate, M.; Banerjee, T.; Adamovich, A. I.; Smith, N.; Jeon, H.; Dhar, S.; Liu, W.;

Burgess, K.; Chung, D.; et al. Multiplexed assay of variant effect reveals residues of functional

importance in the BRCA1 coiled-coil and serine cluster domains. *PLoS One* **2023**, *18* (11),

e0293422. DOI: 10.1371/journal.pone.0293422 From NLM Medline.

(17) Esposito, D.; Weile, J.; Shendure, J.; Starita, L. M.; Papenfuss, A. T.; Roth, F. P.; Fowler, D.

M.; Rubin, A. F. MaveDB: an open-source platform to distribute and interpret data from

multiplexed assays of variant effect. *Genome Biol* **2019**, *20* (1), 223. DOI: 10.1186/s13059-019-

1845-6 From NLM Medline.

(18) Feng, B. J. PERCH: A Unified Framework for Disease Gene Prioritization. *Hum Mutat* **2017**,

38 (3), 243-251. DOI: 10.1002/humu.23158 From NLM Medline.

(19) Ioannidis, N. M.; Rothstein, J. H.; Pejaver, V.; Middha, S.; McDonnell, S. K.; Baheti, S.;

Musolf, A.; Li, Q.; Holzinger, E.; Karyadi, D.; et al. REVEL: An Ensemble Method for Predicting

the Pathogenicity of Rare Missense Variants. *Am J Hum Genet* **2016**, *99* (4), 877-885. DOI: 10.1016/j.ajhg.2016.08.016 From NLM Medline.

(20) Carter, H.; Douville, C.; Stenson, P. D.; Cooper, D. N.; Karchin, R. Identifying Mendelian disease genes with the variant effect scoring tool. *BMC Genomics* **2013**, *14 Suppl 3* (Suppl 3), S3. DOI: 10.1186/1471-2164-14-S3-S3 From NLM Medline.

(21) Martin, F. J.; Amode, M. R.; Aneja, A.; Austine-Orimoloye, O.; Azov, A. G.; Barnes, I.; Becker, A.; Bennett, R.; Berry, A.; Bhai, J.; et al. Ensembl 2023. *Nucleic Acids Res* **2023**, *51* (D1), D933-D941. DOI: 10.1093/nar/gkac958 From NLM Medline.

(22) Liu, X.; Li, C.; Mou, C.; Dong, Y.; Tu, Y. dbNSFP v4: a comprehensive database of transcript-specific functional predictions and annotations for human nonsynonymous and splice-site SNVs. *Genome Med* **2020**, *12* (1), 103. DOI: 10.1186/s13073-020-00803-9 From NLM Medline.

(23) Pejaver, V.; Urresti, J.; Lugo-Martinez, J.; Pagel, K. A.; Lin, G. N.; Nam, H. J.; Mort, M.; Cooper, D. N.; Sebat, J.; Iakoucheva, L. M.; et al. Inferring the molecular and phenotypic impact of amino acid variants with MutPred2. *Nat Commun* **2020**, *11* (1), 5918. DOI: 10.1038/s41467-020-19669-x From NLM Medline.

(24) Cheng, J.; Novati, G.; Pan, J.; Bycroft, C.; Zemgulyte, A.; Applebaum, T.; Pritzel, A.; Wong, L. H.; Zielinski, M.; Sargeant, T.; et al. Accurate proteome-wide missense variant effect prediction with AlphaMissense. *Science* **2023**, *381* (6664), eadg7492. DOI: 10.1126/science.adg7492 From NLM Medline.

(25) Tavtigian, S. V.; Deffenbaugh, A. M.; Yin, L.; Judkins, T.; Scholl, T.; Samollow, P. B.; de Silva, D.; Zharkikh, A.; Thomas, A. Comprehensive statistical study of 452 BRCA1 missense substitutions with classification of eight recurrent substitutions as neutral. *J Med Genet* **2006**, *43* (4), 295-305. DOI: 10.1136/jmg.2005.033878 From NLM Medline.

(26) Mathe, E.; Olivier, M.; Kato, S.; Ishioka, C.; Hainaut, P.; Tavtigian, S. V. Computational

approaches for predicting the biological effect of p53 missense mutations: a comparison of three

sequence analysis based methods. *Nucleic Acids Res* **2006**, *34* (5), 1317-1325. DOI:

10.1093/nar/gkj518 From NLM Medline.

(27) Bergquist, T.; Stenton, S. L.; Nadeau, E. A. W.; Byrne, A. B.; Greenblatt, M. S.; Harrison, S.

M.; Tavtigian, S. V.; O'Donnell-Luria, A.; Biesecker, L. G.; Radivojac, P.; et al. Calibration of

additional computational tools expands ClinGen recommendation options for variant

classification with PP3/BP4 criteria. *bioRxiv* **2024**. DOI: 10.1101/2024.09.17.611902 From NLM

PubMed-not-MEDLINE.

(28) Li, H.; LaDuca, H.; Pesaran, T.; Chao, E. C.; Dolinsky, J. S.; Parsons, M.; Spurdle, A. B.;

Polley, E. C.; Shimelis, H.; Hart, S. N.; et al. Classification of variants of uncertain significance in

BRCA1 and BRCA2 using personal and family history of cancer from individuals in a large

hereditary cancer multigene panel testing cohort. *Genet Med* **2020**, *22* (4), 701-708. DOI:

10.1038/s41436-019-0729-1 From NLM Medline.

(29) Easton, D. F.; Deffenbaugh, A. M.; Pruss, D.; Frye, C.; Wenstrup, R. J.; Allen-Brady, K.;

Tavtigian, S. V.; Monteiro, A. N.; Iversen, E. S.; Couch, F. J.; et al. A systematic genetic

assessment of 1,433 sequence variants of unknown clinical significance in the BRCA1 and

BRCA2 breast cancer-predisposition genes. *Am J Hum Genet* **2007**, *81* (5), 873-883. DOI:

10.1086/521032 From NLM Medline.

(30) Trapp, O.; Seeliger, K.; Puchta, H. Homologs of breast cancer genes in plants. *Front Plant*

Sci **2011**, *2*, 19. DOI: 10.3389/fpls.2011.00019 From NLM PubMed-not-MEDLINE.

(31) Keeling, P. J.; Burki, F. Progress towards the Tree of Eukaryotes. *Curr Biol* **2019**, *29* (16),

R808-R817. DOI: 10.1016/j.cub.2019.07.031 From NLM Medline.

(32) Al Jewari, C.; Baldauf, S. L. An excavate root for the eukaryote tree of life. *Sci Adv* **2023**, *9*

(17), eade4973. DOI: 10.1126/sciadv.ade4973 From NLM Medline.

(33) Parsons, M. T.; de la Hoya, M.; Richardson, M. E.; Tudini, E.; Anderson, M.; Berkofsky-

Fessler, W.; Caputo, S. M.; Chan, R. C.; Cline, M. S.; Feng, B. J.; et al. Evidence-based

recommendations for gene-specific ACMG/AMP variant classification from the ClinGen ENIGMA

BRCA1 and BRCA2 Variant Curation Expert Panel. *Am J Hum Genet* **2024**, *111* (9), 2044-2058.

DOI: 10.1016/j.ajhg.2024.07.013 From NLM Medline.

(34) Grimm, D. G.; Azencott, C. A.; Aicheler, F.; Gieraths, U.; MacArthur, D. G.; Samocha, K. E.;

Cooper, D. N.; Stenson, P. D.; Daly, M. J.; Smoller, J. W.; et al. The evaluation of tools used to

predict the impact of missense variants is hindered by two types of circularity. *Hum Mutat* **2015**,

36 (5), 513-523. DOI: 10.1002/humu.22768 From NLM Medline.

(35) Starita, L. M.; Ahituv, N.; Dunham, M. J.; Kitzman, J. O.; Roth, F. P.; Seelig, G.; Shendure,

J.; Fowler, D. M. Variant Interpretation: Functional Assays to the Rescue. *Am J Hum Genet*

2017, *101* (3), 315-325. DOI: 10.1016/j.ajhg.2017.07.014 From NLM Medline.

(36) Fowler, D. M.; Rehm, H. L. Will variants of uncertain significance still exist in 2030? *Am J*

Hum Genet **2024**, *111* (1), 5-10. DOI: 10.1016/j.ajhg.2023.11.005 From NLM Medline.

FIGURE LEGENDS

Figure 1. Description of study flow

Functional assay results were combined with other data types (Exceptionally Conserved

Ancestral Residue (ECAR) or computational tool prediction) to evaluate the additivity

assumptions in the ACMG guidelines. Table 1: Tabulation of the number of functionally abnormal

variants (red line) that fall at ECAR positions. Table 2: A case control analysis and conversion to

ACMG points is then performed on these variants and results. Table 3: Functionally abnormal

variants that do not fall at ECAR positions are combined with predictions from six computational

tools, followed by a case control analysis and conversion to ACMG points. Table 4: Functionally

normal variants (blue line) from the assay are combined with computational tool predictions from

the same six tools, followed by a case control analysis and conversion to ACMG points.

Figure 2. Graphical Summary of Results

The matrix represents the main combinations of evidence evaluated in this study. The number in

the row or column headers represent the Bayesian point value assigned to each evidence type in

the ACMG guidelines. Each box has three lines: Expectation, Observed, and Percent of calls.

"Expectation" is the Bayesian points expected according to the ACMG guidelines. The

combination of ECAR, MAVE loss of function, and computational tool pathogenic was capped at

≥+6 points. Otherwise expected points per category are additive as described in the ACMG

guidelines. The Observed line represents the Bayesian point value that was observed using the

MLE model in this study. The Percent all calls line represents the range, as a percent, of all

possible substitutions that were observed for a particular combination of evidence for the

computational tools evaluated. Blue filled boxes indicate that the combination of evidence met or

exceeded the ACMG guideline expectations in this study. Peach filled boxes indicate that the

combination of evidence departed from the expected additivity of the ACMG guideline in this

study. The bold black outline highlights that the assumption that MAVE LOF and computational

predictions of pathogenicity are additive is not met in this study; moreover, this combination had

a substantial number of observations. White filled boxes represent combinations of evidence

with little to no data. Dark grey filled boxes represent combinations of evidence with results that

may be beyond the dynamic range of the MLE model.

Table 1. Predictions from SGE Functional Assay and Computational Tools at ECAR Positions.

Residue	Total Number of Possible snMS	LOF in SGE	Number of +4 Calls made by:					Other Models:	
			AlphaMissense	BayesDel	MutPred2	REVEL	VEST4	BayesDel-VCEP[a]	A-GVGD
C24	6	5	6	5	0	5	1	6	6
C27	6	6	4	5	0	5	0	6	6
C39	6	6	5	6	0	4	2	6	6
H41	7	7	2	6	0	3	0	7	5
C44	6	6	5	6	0	4	0	6	6
C47	6	6	6	6	0	2	3	6	6
C61	6	5	5	6	0	4	2	6	6
C64	6	6	4	6	0	5	4	6	6
T1685	5	5	0	0	0	0	0	3	1
H1686	7	7	0	0	0	0	0	6	5
T1700	6	5	0	0	0	0	0	6	3
W1718	5	4	1	5	0	2	0	5	4
R1753	5	5	0	0	0	0	0	5	4
W1837	5	5	2	5	0	0	0	5	4
Totals at ECAR positions	82	78[b]	41	56	0	34	12	79	68
Total ECAR snMS with LOF in SGE	78	78	39	53	0	32	11	75	65
Totals with LOF via SGE assay	404	404	52	67	0	33	11	301	183
Totals in RING/tBRCT domains	1,840	404	60	73	1	35	12	530	267
Totals across BRCA1	11,009	NA	60	122	1	45	12	846	314

ECAR = Exceptionally Conserved Ancestral Residue
snMS = Single Nucleotide Missense Substitution
LOF = Loss of Function
SGE = Saturation Genome Editing
VCEP = Variant Curation Expert Panel

a. VCEP thresholds divide 'BayesDel no AF' scores into supporting benign, supporting pathogenic, and indeterminate scores. Scores ≥ 0.28 are supporting pathogenic.

b. 4 variants at ECAR positions were not LOF. C24F, C61R, and W1718S had indeterminate results. T1700S was not interrogated in the assay.

Table 2. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Functional Assay Analytical Subsets and Non-functional Substitutions Falling at ECAR Positions.

	Possible snMS[a]	Unique Variant Obs.	Clinical Obs.	gnomAD Obs.	Adjusted OR[b]	95% C.I.	M.L.E Proportion Pathogenic[c]	Estimated ACMG Point[d]	Expected ACMG Point[e]
Nonsense Substitutions	NA	213	1078	68	21.6	16.9 – 27.7	NA	NA	
M2H Assay Categories									
Functional	452	56	58	75	1.21	0.85 – 1.72	0.01	-3	-4
Indeterminate	17	1	14	0	NA	NA	NA	NA	0
Non-Functional – All	100	24	235	13	22.6	12.9 – 39.5	1.00	4	4
Non-functional – ECAR	50	14	220	11	24.8	13.5 – 45.6	1.00	≥ 6	6
Non-functional – Other	50	10	15	2	21.6	2.23 – 43.9	0.74	4	4
SGE Assay Categories									
Functional	1,185	154	121	239	0.80	0.64 – 1.00	0.00	-4	-4
Indeterminate	148	28	36	24	2.51	1.48 – 4.25	0.16	0	0
Non-Functional – All	413	77	413	37	16.3	11.6 – 27.7	0.88	4	4
Non-functional – ECAR	89	19	231	11	26.2[h]	14.3 – 48.1	1.00	≥ 6	6
Non-functional – Other	324	58	182	26	12.0[h]	7.9 – 18.1	0.71	4	4
HDR Assay Categories									
Functional	152	14	26	27	1.32	0.76 – 2.29	0.05	-1	-4
Indeterminate	15	2	0	15	NA	NA	NA	NA	0
Non-Functional – All	16	2	1	1	1.48	0.87 – 25.2	0.06	0	4
A Priori Damaging[f]	22[g]	5	1	4	0.46	0.50 – 4.24	0.00	-4	2

ACMG = American College of Medical Genetics and Genomics
ECAR = Exceptionally Conserved Ancestral Residue
snMS = Single Nucleotide Missense Substitution
Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable
M2H = Mammilian-2-Hybrid

SGE = Saturation Genome Editing
ECAR = Exceptionally Conserved Ancestral Residue
HDR = Homology Directed Repair
a. Restricted to those snMS interrogated in the assay indicated.
b. Adjusted for race/ethnicity.
c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.
d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
e. The expected points from combining evidence categories according to ACMG guidelines.
f. This subset interrogates the substitutions to Proline and other non-conservative amino acid substitutions that fell at the a,d positions of the alpha helix in the coiled-coil domain (M1400, Q1401, H1402, L1404, L1407, Q1408, Q1409, M1411, A1412, L1414, A1416, L1418), regardless of whether they were interrogated in the assay. Only Q1401P was included in the assay and had no clinical or gnomAD observations in our dataset.
g. This is the total number of possible substitutions listed in footnote e. irrespective of inclusion in the HDR assay of the coiled coil domain.
h. Indicates that these ORs are statistically significant from one another.

Table 3. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Non-functional, Non-ECAR Assay Results Combined with Computational Predictions.

Computational Tool Prediction	Possible snMS[a]	Unique Variants Obs.	Clinical Obs.	gnomAD Obs.	Adjusted OR[b]	95% C.I.	M.L.E Proportion Pathogenic[c]	Estimated ACMG Point[d]	Expected ACMG Point[e]
A-GVGD									
Pathogenic	120	23	95	11	14.9	7.97 – 28.0	0.79	4	5
Indeterminate	120	20	71	11	10.9	5.72 – 20.6	0.68	3	4
Benign	91	15	16	4	6.80	2.24 – 20.6	0.49	2	3
AlphaMissense									
Pathogenic	232	43	171	19	15.4	9.56 – 24.8	0.81	4	5
Indeterminate	80	14	9	7	2.03	0.86 – 10.4	0.12	1	4
Benign	13	1	2	0	NA	NA	NA	NA	3
BayesDel									
Pathogenic	284	52	175	25	11.9	7.80 – 18.2	0.71	4	5
Indeterminate	46	6	7	1	13.5	1.64 – 110.8	0.71	4	4
Benign	0	0	0	0	NA	NA	NA	NA	3
BayesDel - VCEP									
Pathogenic	231	47	170	23	12.6	8.14 – 19.6	0.73	4	5
Indeterminate	45	5	5	2	3.62	0.68 – 19.2	0.32	1	4
Benign	55	6	7	1	13.5	1.64 – 110.8	0.71	4	3
MutPred2									
Pathogenic	142	30	115	15	13.4	7.82 – 23.7	0.75	4	5
Indeterminate	159	25	65	10	10.6	5.40 – 20.7	0.68	3	4
Benign	29	3	2	1	3.52	0.31 – 40.4	0.24	1	3
REVEL									
Pathogenic	285	52	175	25	11.9	7.80 – 18.3	0.71	4	5
Indeterminate	46	6	7	1	13.5	1.64 – 110.8	0.71	4	4
Benign	0	0	0	0	NA	NA	NA	NA	3
VEST4									
Pathogenic	213	43	167	21	13.5	8.54 – 21.3	0.76	4	5
Indeterminate	108	15	15	5	5.49	1.97 – 15.3	0.38	2	4
Benign	10	0	0	0	NA	NA	NA	NA	3

ACMG = American College of Medical Genetics and Genomics
ECAR = Exceptionally Conserved Ancestral Residue
snMS = Single Nucleotide Missense Substitution
Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable
VCEP = Variant Curation Expert Panel
a. Restricted to those snMS interrogated in the assay indicated.
b. Adjusted for race/ethnicity.
c. The OR threshold used for this calculation is that of the nonsense variants observed in our case/control dataset.
d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
e. The expected points from combining evidence categories according to ACMG guidelines.

Table 4. Odds Ratios, Proportions Pathogenic, and ACMG Point Estimates of Functionally Normal Assay Results Combined with Computational Predictions.

Computational Tool Prediction	Possible snMS[a]	Unique Variant Obs.	Clinical Obs.	gnomAD Obs.	Adjusted OR[b]	95% C.I.	M.L.E Proportion Pathogenic[c]	Estimated ACMG Point[d]	Expected ACMG Point[e]
A-GVGD									
Pathogenic	61	9	11	8	2.53[f]	1.00 – 6.38	0.32	1	-3
Indeterminate	212	25	40	43	1.45	0.93 – 2.26	0.10	0	-4
Benign	912	120	70	188	0.58[f]	0.44 – 0.77	0.00	-5	-5
AlphaMissense									
Pathogenic	122	19	19	17	1.70[f]	0.87 – 3.32	0.20	1	-3
Indeterminate	586	78	78	115	1.07	0.80 – 1.44	0.00	-4	-4
Benign	477	57	24	107	0.36[f]	0.23 – 0.56	0.00	-5	-5
BayesDel									
Pathogenic	379	54	65	77	1.36	0.97 – 1.90	0.06	0	-3
Indeterminate	769	95	54	155	0.54	0.36 – 0.74	0.00	-4	-4
Benign	37	5	2	7	0.52	0.11 – 2.55	0.00	-5	-5
BayesDel - VCEP									
Pathogenic	152	20	21	28	1.21[f]	0.68 – 2.15	0.00	-4	-3
Indeterminate	181	29	35	45	1.20	0.76 – 0.83	0.02	-3	-4
Benign	852	105	65	166	0.62[f]	0.46 – 0.83	0.00	-5	-5
MutPred2									
Pathogenic	86	6	4	7	1.10	0.32 – 3.81	0.00	-4	-3
Indeterminate	399	57	62	79	1.14	0.81 – 1.61	0.02	-2	-4
Benign	697	91	55	153	0.60	0.44 – 0.82	0.00	-5	-5
REVEL									
Pathogenic	413	52	56	85	1.08	0.77 – 1.52	0.00	-4	-3
Indeterminate	769	102	65	154	0.49	0.36 – 0.68	0.00	-4	-4
Benign	3	0	0	0	NA	NA	NA	NA	-5
VEST4									
Pathogenic	116	14	19	15	2.56[f]	1.29 – 5.07	0.27	1	-3
Indeterminate	763	100	84	139	0.88	0.67 – 1.16	0.00	-4	-4
Benign	306	40	18	85	0.37[f]	0.22 – 0.62	0.00	-5	-5

ACMG = American College of Medical Genetics and Genomics
snMS = Single Nucleotide Missense Substitution
Obs. = Observations
OR = Odds Ratio
C.I. = Confidence Interval
M.L.E = Maximum Likelihood Estimate
NA = Not Applicable
VCEP = Variant Curation Expert Panel
a. Restricted to those snMS interrogated in the assay indicated.
b. Adjusted for race/ethnicity.
c. The OR threshold used for this calculation is that of moderate risk variants (OR = 2) adjusted for observational inflation in our data to OR = 4.4.
d. The maximum allowed points are capped as specified in ACMG variant classification guidelines per evidence category/combination of evidence categories.
e. The expected points from combining evidence categories according to ACMG guidelines.
f. Indicates that these ORs are statistically significant from one another. Comparison is made between the predicted benign and predicted pathogenic categories for a given computational tool.

Figure 1

Alignment → ECARs

Functional Results

Table 1

Case Control Analyses → MLE Estimated Proportion Pathogenic

Table 2

AGVGD, AlphaMissense, BayesDel, MutPred2, REVEL, VEST4

Table 3

Table 4

~BRCA1s

~BARD1s

Figure 2

		Substitution at ECAR (+2)		Substitution at non-ECAR (+0)	
		MAVE LOF (+4)	MAVE Functional (-4)	MAVE LOF (+4)	MAVE Functional (-4)
Computational Prediction	Pathogenic (+1)	Expectation: ≥+6 ACMG Points Observed: ≥+6 Percent of calls: (2.67% - 4.25%)	Expectation: -1 ACMG Points Observed: NA Percent of calls: (0.00%)	Expectation: +5 ACMG Points Observed: +4 Percent of calls: (6.42% - 15.24%)	Expectation: -3 ACMG Points Observed: -4 to +1 Percent of calls: (3.32% - 22.65%)
	Benign (-1)	Expectation: +5 ACMG Points Observed: NA Percent of calls: (0.00% - 0.11%)	Expectation: -3 ACMG Points Observed: NA Percent of calls: (0.00%)	Expectation: +3 ACMG Points Observed: +1 to +4 Percent of calls: (0.00% - 4.90%)	Expectation: -5 ACMG Points Observed: ≤-5 Percent of calls: (0.16% - 54.98%)

= Meets or exceeds expectations   = Departs from expected additivity   = Scant Observations

= Limited sensitivity between invdividual points